About: Unmasking Differential Effects of Rosiglitazone and Pioglitazone in the Combination Treatment with n-3 Fatty Acids in Mice Fed a High-Fat Diet

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Unmasking Differential Effects of Rosiglitazone and Pioglitazone in the Combination Treatment with n-3 Fatty Acids in Mice Fed a High-Fat Diet Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
Description	We investigated whether pioglitazone (as well as rosiglitazone), a TZD-drug, could elicit the additive beneficial effects when combined with n-3 LC-PUFA. Adult male mice were fed a high-fat diet (cHF) for 8 weeks, or randomly assigned to various dietary treatments (i) cHF+F, cHF with n-3 LC-PUFA concentrate replacing 15% of dietary lipids; (ii) cHF+ROSI, cHF with rosiglitazone; (iii) cHF+F+ROSI; (iv) cHF+PIO, cHF with pioglitazone; and (v) cHF+F+PIO, or chow-fed. Plasma concentrations of 163 metabolites, development obesity, glucose homeostasis, plasma lipid levels and gene expression were evaluated. Both TZDs preserved glucose homeostasis and normal plasma lipid levels while inducing adiponectin. The beneficial effects of TZDs were further augmented by the combination treatments. Our results reveal differential effects of rosiglitazone and pioglitazone and support the notion that n-3 LC-PUFA could be used as add-on treatment to TZDs in order to improve diabetic patient’s therapy We investigated whether pioglitazone (as well as rosiglitazone), a TZD-drug, could elicit the additive beneficial effects when combined with n-3 LC-PUFA. Adult male mice were fed a high-fat diet (cHF) for 8 weeks, or randomly assigned to various dietary treatments (i) cHF+F, cHF with n-3 LC-PUFA concentrate replacing 15% of dietary lipids; (ii) cHF+ROSI, cHF with rosiglitazone; (iii) cHF+F+ROSI; (iv) cHF+PIO, cHF with pioglitazone; and (v) cHF+F+PIO, or chow-fed. Plasma concentrations of 163 metabolites, development obesity, glucose homeostasis, plasma lipid levels and gene expression were evaluated. Both TZDs preserved glucose homeostasis and normal plasma lipid levels while inducing adiponectin. The beneficial effects of TZDs were further augmented by the combination treatments. Our results reveal differential effects of rosiglitazone and pioglitazone and support the notion that n-3 LC-PUFA could be used as add-on treatment to TZDs in order to improve diabetic patient’s therapy (en)
Title	Unmasking Differential Effects of Rosiglitazone and Pioglitazone in the Combination Treatment with n-3 Fatty Acids in Mice Fed a High-Fat Diet Unmasking Differential Effects of Rosiglitazone and Pioglitazone in the Combination Treatment with n-3 Fatty Acids in Mice Fed a High-Fat Diet (en)
skos:prefLabel	Unmasking Differential Effects of Rosiglitazone and Pioglitazone in the Combination Treatment with n-3 Fatty Acids in Mice Fed a High-Fat Diet Unmasking Differential Effects of Rosiglitazone and Pioglitazone in the Combination Treatment with n-3 Fatty Acids in Mice Fed a High-Fat Diet (en)
skos:notation	RIV/67985823:_____/11:00367620!RIV12-MZ0-67985823
http://linked.open...avai/predkladatel	Fyziologický ústav AV ČR, v.v.i.
http://linked.open...avai/riv/aktivita	P Z
http://linked.open...avai/riv/aktivity	P(NS10528), Z(AV0Z50110509)
http://linked.open...iv/cisloPeriodika	11
http://linked.open...vai/riv/dodaniDat	2012
http://linked.open...aciTvurceVysledku	Kopecký, Jan Flachs, Pavel Macek Jílková, Zuzana Bardová, Kristina Kůs, Vladimír Rossmeisl, Martin Kuda, Ondřej Janovská, Petra Svobodová, Michaela
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Fyziologický ústav AV ČR, v. v. i.
http://linked.open...dnocenehoVysledku	236899
http://linked.open...ai/riv/idVysledku	RIV/67985823:_____/11:00367620
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	obesity; TZD; fish oil (en)
http://linked.open.../riv/klicoveSlovo	fish oil TZD obesity
http://linked.open...odStatuVydavatele	US - Spojené státy americké
http://linked.open...ontrolniKodProRIV	[5E2D7608354A]
http://linked.open...i/riv/nazevZdroje	PLoS ONE
http://linked.open...in/vavai/riv/obor	FB
http://linked.open...ichTvurcuVysledku	9 (xsd:int)
http://linked.open...cetTvurcuVysledku	12 (xsd:int)
http://linked.open...vavai/riv/projekt	Aditive effects of omega-3 polyunsaturated fatty acids and pioglitazone in the treatment of type 2 diabetes mellitus
http://linked.open...UplatneniVysledku	2011
http://linked.open...v/svazekPeriodika	6
http://linked.open...iv/tvurceVysledku	Kopecký, Jan Bardová, Kristina Flachs, Pavel Macek Jílková, Zuzana Kůs, Vladimír Janovská, Petra Kuda, Ondřej Rossmeisl, Martin Svobodová, Michaela Illig, T. Wang-Sattler, R. Yu, Z.
http://linked.open...ain/vavai/riv/wos	000297197000028
http://linked.open...n/vavai/riv/zamer	Výzkum molekulárních a buněčných základů fyziologických a patofyziologických procesů s cílem objasnit mechanismy vzniku závažných onemocnění člověka
issn	1932-6203
number of pages	14 (xsd:int)
http://bibframe.org/vocab/doi	10.1371/journal.pone.0027126
is http://linked.open...avai/riv/vysledek of	Unmasking Differential Effects of Rosiglitazone and Pioglitazone in the Combination Treatment with n-3 Fatty Acids in Mice Fed a High-Fat Diet Unmasking Differential Effects of Rosiglitazone and Pioglitazone in the Combination Treatment with n-3 Fatty Acids in Mice Fed a High-Fat Diet

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 58 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software